Neoadjuvant Chemoradiotherapy Versus Perioperative Chemotherapy ± Immunotherapy in Resectable Esophageal Adenocarcinoma.

Authors

Aroub Alkaaki, Nianye Zheng, Nicolas Toumbacaris, Siqi Chen, Kay See Tan, David B Sewell, Bernard J Park, David R Jones, Katherine D Gray, Matthew J Bott, Smita Sihag, Yelena Janjigian, Abraham Wu, Daniela Molena

Published in

The Journal of thoracic and cardiovascular surgery. Sep 23, 2026. Epub Sep 23, 2026.

Abstract

We sought to compare pathologic responses, perioperative outcomes, and early survival between induction chemoradiotherapy and perioperative chemotherapy ± immunotherapy in patients with resectable esophageal adenocarcinoma.
Using our prospectively maintained institutional database, we retrospectively identified adult patients with resectable, locally advanced esophageal or gastroesophageal junction adenocarcinoma who underwent esophagectomy from January 2013 to October 2024 after induction chemoradiotherapy or perioperative chemotherapy ± immunotherapy. The primary outcome was rate of pathologic complete response. Secondary outcomes included rate of microscopically margin-negative resection, rate of pathologic node-negative status, and perioperative morbidity. Event-free survival and overall survival were estimated using Kaplan-Meier methods and were evaluated using Cox regression.
Of 811 patients, 650 (80%) received chemoradiotherapy, and 161 (20%) received chemotherapy ± immunotherapy. Median follow-up was 29.9 months. Chemoradiotherapy was associated with higher rates of pathologic complete response (23% vs. 14%) and pathologic node-negative status (61% vs. 46%; both P<0.001 after adjustment). The rate of microscopically margin-negative resection was 96% in both groups. Two-year event-free survival was higher in the chemotherapy ± immunotherapy group (66% vs. 53%; adjusted hazard ratio, 0.53; P=0.007). Two-year overall survival was not statistically different between groups. On multivariable analysis, perioperative chemotherapy ± immunotherapy and pathologic complete response were independently associated with longer event-free survival.
Both induction strategies achieved excellent perioperative outcomes. Despite higher rates of pathologic complete response with chemoradiotherapy, perioperative chemotherapy ± immunotherapy was associated with longer early event-free survival. This association was attenuated in propensity score-matched and 90-day landmark analyses. Longer follow-up is warranted.

PMID:
42777942
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.